Novo bets on 'triple G' obesity drug in up to $2 billion deal with Chinese biotech
Danish drugmaker Novo Nordisk has bought global rights to China-based United Laboratories International's so-called "triple-G ...
Novo licenses Chinese biotech's obesity drug candidate for up to $2 billion
(Reuters) -Danish drugmaker Novo Nordisk has secured the global rights to develop, manufacture and sell China-based United ...
Alwihda Info2d
China accelerated national development of weight management clinics to combat obesity
A recent follow-up assessment at the USTC hospital's multidisciplinary weight management clinic demonstrated the efficacy of ...
Obesity will affect over half of adults in 25 years, study predicts
Obesity has long been classified as a global epidemic — and new data published in The Lancet journal spotlights how much ...
Stocktwits on MSN11d
Novo Nordisk Signs $2B Deal For Obesity Drug With Chinese Biotech: Retail Sentiment Improves
Drugmaker Novo Nordisk A/S (NVO) on Monday entered into an exclusive license agreement worth up to $2 billion with ...
朝日新聞社5d
China to prioritize physical education in schools as obesity rates rise
Obesity in girls rose to 7.7% in 2022 from 0.6% in 1990. “Obesity has become a major public health issue in China, ranking as the sixth leading risk factor for death and disability in the ...
Novo Nordisk To Pay Around $2 Billion For Obesity Drug From China-Based Biotech
Novo Nordisk secures global rights (excluding China) for UBT251 in a $2B+ deal with United Biotechnology, advancing obesity ...
BioPharma Dive11d
Novo adds to obesity drug pipeline via $200M deal with China-based biotech
The licensing pact adds a second so-called "triple agonist" to the Danish drugmaker's portfolio as competition with Lilly and ...
In the obesity triple-agonist blockbuster race, a familiar battle looms: Novo vs. Lilly
The two market leaders are targeting new obesity alternatives in their pipelines with an eye toward a triple threat.
Yahoo Finance11d
Novo adds to obesity drug pipeline via $200M deal with China-based biotech
Novo Nordisk is expanding its pipeline of obesity medicines, announcing Monday it will pay China-based United Laboratories International Holdings $200 million upfront to license an experimental ...